Brief: MannKind To Acquire scPharmaceuticals
25/08/2025 12:33
Aug 25 (Reuters) - MannKind Corp MNKD.O: MANNKIND TO ACQUIRE SCPHARMACEUTICALS, ACCELERATING REVENUE GROWTH AND EMERGING AS A PATIENT-CENTRIC LEADER IN CARDIOMETABOLIC AND LUNG DISEASES MANNKIND CORP - DEAL FOR UPFRONT CASH PAYMENT OF $5.35 PER SHARE PLUS CVR MANNKIND CORP - TOTAL EQUITY VALUE $303 MILLION, DEAL VALUE UP TO $360 MILLION MANNKIND CORP - CO AND BLACKSTONE AMEND FINANCING AGREEMENT FOR $175 MILLION Source text: ID:nGNX4Dd9pp Further company coverage: MNKD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children